NCT01012362View on ClinicalTrials.gov

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Breast CancerLung CancerColon CancerPancreatic CancerHead and Neck CancerKidney CancerSarcomaHepatocellular Cancer
Interventions
DRUG

Pazopanib

Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.

DRUG

Ixabepilone

Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT01012362 - Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter